Investor Presentation

Registered & Corporate Office: AMANTA HEALTHCARE LIMITED 8th Floor, Shaligram Corporates, CJ Marg, Ambli, Ahmedabad–380058, Gujarat, INDIA. Tel.: 079 – 67777600 Email: info@amanta.co.in Website: www.amanta.co.in CIN: L24139GJ1994PLC023944 November 4, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Phiroze Jeejeebhoy Towers, Bandra Kurla Complex Dalal Street, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Scrip Code: 544502 Trading Symbol: AMANTA Dear Sir/ Madam, Sub: Investors Presentation on Financial Results of the Company for the quarter and half year ended September 30, 2026 Please find enclosed the Investors Presentation on Financial Results of the Company for the quarter and half year ended September 30, 2026. You are requested to take the same on your records. Thanking you. Yours sincerely, For AMANTA HEALTHCARE LIMITED NIKHITA DINODIA COMPANY SECRETARY & COMPLIANCE OFFICER Encl.: As above Factory: 876, N.H. No. 8, Hariyala, Kheda – 387411, Gujarat, India. Tel 2694287700 Fax 2694287720 Amanta Healthcare Limited Q2 & H1 FY27 Investor Presentation November, 2026 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Amanta Healthcare Ltd. (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containingdetailedinformationabouttheCompany. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation.ThisPresentationmaynotbeallinclusiveandmaynotcontainalloftheinformationthatyoumayconsidermaterial.Anyliabilityinrespectofthecontentsof,orany omissionfrom, thisPresentation isexpresslyexcluded.Certain mattersdiscussed inthisPresentation maycontain statementsregardingtheCompany’s market opportunityand businessprospectsthat areindividually and collectivelyforward-looking statements.Such forward-looking statementsarenotguaranteesoffutureperformanceand aresubject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, incomeorcashflows,theCompany’s market preferencesand itsexposuretomarket risks,aswellasother risks.TheCompany’s actualresults,levels ofactivity,performanceor achievementscould differmateriallyand adverselyfromresultsexpressedinorimpliedbythisPresentation.TheCompanyassumes noobligationtoupdate anyforward-looking information containedinthisPresentation.Any forward-looking statementsand projections made bythird parties includedinthisPresentation arenotadoptedbythe Company andtheCompanyisnotresponsibleforsuchthird-partystatementsandprojections. S E C T I O N 0 1 Performance Q2 & H1 FY27 Financial Highlights The capacity-led growth phase begins Strategic Highlights Q2FY27 topline grows 17% with PAT growth of 26% YoY basis 01 02 Financial performance SteriPort Line 3 is live • Q2 FY27 revenue ₹83.13 Cr, 17.3% YoY • Commissioned in the first week of September 2026 at the existing Kheda facility • Q2 FY27 EBITDA ₹17.95 Cr; margin 21.6%, resulting in PAT of ₹4.86Cr with a margin of 6% • SteriPort capacity up 75%: 6.6 Cr → 11.6 Cr bottles • H1 FY27 revenue ₹151.94Cr; PAT ₹8.17Cr. • ~₹60 Cr revenue expected in FY27; ₹110–120 Cr a year at optimal utilisation 03 04 SVP expansion next Cost and balance sheet • Capacity to rise from 20.9 Cr to 31.7 Cr unitsduring Q1 of FY28. • 10.8 MW captive solar generating since end-Q1 FY27; ~₹9 Cr annual power savings • Adds inhalation, ophthalmics and diluents in the highest-margin segment (22–27% EBITDA) • Debt-to-equity down from 3.5x (FY23) to ~1.1x (FY26) 20%+ 25%+ Two-year aim: Revenue CAGR | EBITDA margin Financial Performance – Q2FY27 (Figures in INR Cr.) Revenue EBITDA and Margins (%) PAT and Margins (%) 21% 22% 2% 6% Q2FY26 Q2FY27 Q2FY26 Q2FY27 Q2FY26 Q2FY27 Revenue PAT and Margins (%) EBITDA and Margins (%) 22% 22% 5% 6% Q1FY27 Q2FY27 Q1FY27 Q2FY27 Q1FY27 Q2FY27 Profit and Loss Statement (Figures in Rs. crs) Particulars Q2FY27 Q2FY26 YoY H1FY27 H1FY26 YOY Revenues 83 71 17% 152 136 12% OtherIncome 1 0 - 1 1 36% TotalIncome 84 71 18% 153 137 12% Cost of materials consumed 28 24 17% 50 48 6% Purchases of stock-in-trade 1 2 -38% 4 5 -18% Changes in inventories of finished goods, work-in- 4 (2) - -1 -11 - process and stock-in-trade Employeecosts 12 11 11% 23 21 12% Otherexpenses 21 22 -5% 43 44 -2% TotalExpenditure 66 56 17% 120 107 13% EBITDA 18 15 22% 33 31 8% Finance Costs 6 5 13% 12 11 4% Depreciation and AmortizationExpenses 5 5 13% 10 9 7% PBT before Exceptional Items 7 5 39% 11 10 15% Exceptional Items - 3 - - 3 - PBT 7 2 - 11 7 57% Tax 2 1 84% 3 2 26% PAT 5 1 303% 8 5 73% Balance Sheet (Figures in Rs. crs) Assets FY26 H1FY27 Equities & Liabilities FY26 H1FY27 Non-Current Assets Equity share capital 39 39 Property, plant and equipment 197 312 Other Equity 181 189 Capital work-in-progress 82 0 Net Worth 220 228 Right-of-use assets 9 8 Non-Current Liabilities Intangible assets 1 1 Non-Current Borrowings 162 49 Non-Current Financial Assets 16 14 Lease Liabilities 8 7 Non current tax assets(Net) 0 1 Deferred Tax Liabilities (Net) 27 29 Other Non-Current Assets 15 15 Total Non-Current Liabilities 197 85 Total Non-Current Assets 320 352 Current Liabilities Current Assets Current Borrowings 72 147 Inventories 83 89 Lease Liabilities 2 2 Trade receivables 43 44 Current Tax Liabilities(Net) 3 3 Cash & Cash Equivalents 81 2 Trade Payables 36 33 Bank Balance Other Than Cash 12 25 Provisions 11 12 Other Financial Assets 0 0 Other Current Liabilities 1 1 Loans 1 0 Other Financial Liabilities 7 8 Other Current Assets 19 16 Contract Liabilities 9 8 Total Current Assets 238 177 Total Current Liabilities 141 216 Total Assets 558 529 Total Equity & Liabilities 558 529 Growth Levers Three pillars working together towards 20%+ revenue CAGR and 25%+ EBITDA margin 01 02 03 MARKET DEPTH MANUFACTURING EFFICIENCY Wallet share expansion Capacity expansion Green energy & cost optimisation • Complex dosages and niche molecules across • SteriPort Line 3 live since Sep 2026: +5.0 Cr • 10.8 MW captive solar; ~₹9 Cr expected annual anti-infectives, respiratory care and ophthalmics bottles saving • Deeper presence in advanced markets • SVP expansion: +10.8 Cr units during Q1 of FY28. • Fixed-cost leverage: new lines share existing infrastructure, workforce and utilities PORTFOLIO New sterile dosage forms CAPACITY +75% SteriPort · +52% SVP SAVINGS ~₹9 Cr a year MILESTONES Q1 FY27 ✓ Sep 2026 ✓ FY27 Q1FY28 Within 12 months Captive solar commissioned SteriPort Line 3 commissioned ~₹60 Cr revenue from Line 3 SVP expansion operational Line 3 at full ramp-up S E C T I O N 0 4 Company Overview Amanta at a Glance I N T H I S S E CT I ON Business model Product portfolio Manufacturing & technology Exports Leadership NICHE PHARMACEUTICAL COMPANY OPERATION AL METRICS FIN ANCIAL METRICS REVENUE CAGR EBITDA CAGR 47 7 1 11% 10% Product portfolio Production lines WHO-GMP facility 30+ Years of FY21–26 FY21–26 320 120 506 Sterile Liquids ROE ROCE 8. [Showing first 8,000 characters — download PDF for full document]